Back

Effects of Angiotensin Receptor/Neprilysin Inhibitor Therapy on NT-proBNP and Cardiac Remodeling in Heart Failure with Reduced Ejection Fraction: Primary Results of the PROVE-HF Study

2 September 2019 (09:06 - 09:24)
Organised by:
Congress Presentation Part of: Late Breaking Science in Heart Failure 1 Pharmacotherapy ESC Premium Access ESC Congress 2019

About the speaker

Photo
Professor James Januzzi

Massachusetts General Hospital - Harvard Medical School, Boston (United States of America)

4 More presentations in this session

Presentation thumbnail
Spironolactone in atrial fibrillation with preserved cardiac contractility
Doctor E. Shantsila (Liverpool, GB)
Slides Video
Presentation thumbnail
Effects of Sacubitril-Valsartan Compared with Enalapril on Arterial Hemodynamics and Cardiac Remodeling in Patients with Heart Failure and Reduced Ejection Fraction
Doctor A. Desai (Boston, US)
Slides Video
Presentation thumbnail
Clinical effectiveness of primary prevention implantable defibrillators: results of the EU-CERT-ICD non-randomised, controlled, multicentre study
Associate Professor M. Zabel (Goettingen, DE)
Slides Video
Presentation thumbnail
Clinical phenotypes, gender differences and adverse events associated with truncating variants in the Titin (TTN) gene
Doctor M. Akhtar (London, GB)
Slides Video

Access the full session

Session thumbnail
Late Breaking Science in Heart Failure 1

The Event

Event poster

ESC Congress 2019

2 September 2019 09:06 CET
You may be interested in
thumbnail
Congress Session
Guideline-directed medical therapy implementation in special clinical scenarios
thumbnail
Congress Session
Meet the Experts: summation of the science - treatment of chronic heart failure in 2023
thumbnail
Webinar
MRAs in heart failure: what's old is new again

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources